The Skin of Color Clinic is devoted to the unique needs of patients of all ethnicities. Photo courtesy of BCM

All skin is created equal, but not all skin behaves the same. It’s with this in mind that Baylor Medicine Dermatology has announced the debut of its newest office.

The Skin of Color Clinic is located inside the Jamail Specialty Care Center and is devoted to the unique needs of patients of all ethnicities.

The leader of the Skin of Color Clinic is assistant professor of dermatology, Oyetewa Oyerinde. Dr. Oyerinde, a Howard University and University of Illinois at Chicago College of Medicine alum, completed her residency training at Harvard University, where she made it to the role of chief resident in her final year.

“I am excited to lead a clinic that addresses skin issues commonly found in underserved populations,” Oyerinde says in a news release. “I want people in Houston to know that there is a place where an expert will know how to care for their specific needs.”

The leader of the Skin of Color Clinic is assistant professor of dermatology, Oyetewa Oyerinde. Photo via bcm.edu

Patients who identify as Black, African American, Latinx, Asian, or Native American all have different skin with varying requirements, which the Skin of Color Clinic will address in a culturally sensitive and competent manner. An awareness that some conditions affect people with darker skin tones differently than people with light skin tones informs the clinic’s work, as does the fact that there are also some diseases that disproportionately affect people of color.

Dr. Oyerinde specializes in issues including hyper- or hypopigmentation, scarring and non-scarring hair loss, acne keloidalis nuchae, and keloids. Meanwhile, Dr. Zeena Nawas will lead the cosmetic wing of the Skin of Color Clinic. Her areas of expertise include chemical peels, laser hair removal and DPN, and skin tag/seborrheic keratosis removal.

“Dr. Oyerinde will excel as the director of the Skin of Color Clinic because of her dedication to providing personalized care for patients of all ethnicities, skin tones and hair textures,” Dr. Ida Orengo, professor and chair of dermatology at Baylor, adds. “The Skin of Color clinic will focus on the treatment of the diverse complexions of our patients and address the gaps in treatment while aiming to correct disparities and help ensure inclusivity in Houston healthcare.”

To further address those disparities, Dr. Oyerinde is planning community outreach events for potential Houston-area patients who may be unaware that clinics like this exist.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.